skip to the content

About Tarceva

Tarceva (erlotinib) is a potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.

Tarceva is a targeted therapy for the treatment of non-small cell lung cancer (NSCLC).



Tarceva EU indications

  • Tarceva is approved for the first-line treatment of EGFR mutation-positive NSCLC1
 
  • Tarceva is also indicated for the treatment of NSCLC in the post-platinum setting (maintenance, second-line and third-line), regardless of mutation status1
 
  • Tarceva is indicated, in combination with gemcitabine, for the treatment of patients with metastatic pancreatic cancer1




Reference

  1. Tarceva® (erlotinib) Summary of Product Characteristics, F. Hoffmann-La Roche Ltd., 2011.

SmPC

The EU product label for Tarceva is available in different languages.

Mechanism of action

Mechanism of Action

Click to access and download the new Tarceva mechanism of action video.

New indication for Tarceva

Tarceva is now approved for first-line therapy of EGFR Mut+ NSCLC.

Tarceva.com

This site is only intended for use by healthcare professionals outside of the US. If you are a US resident, please visit http://www.tarceva.com/.